Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers


Partagez l'article

May 15th – 2020 – CQDM congratulates Theratechnologies and UQAM’s Professor Borhane Annabi for the positive results presented at the Virtual Annual Meeting II of the American Association for Cancer Research (AACR), particularly those obtained with its docetaxel-peptide conjugate TH-1902 for the treatment of triple-negative breast cancer.

These are very encouraging results!

To read Theratechnologies press release, click here.

Scroll to Top